2023-508476-11-00招募中1 期
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Ignasi Riera
Scientific
Remix Therapeutics Inc.
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of RP1 alone and in combination with other therapies in patients with solid tumoursEUCTR2016-004548-12-ESReplimune Inc.300
进行中（未招募）
1 期
Study of RP1 alone and in combination with other therapies in patients with solid tumoursAdvanced solid tumoursMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2016-004548-12-GBReplimune Inc.293
尚未招募
不适用
An open-label, multicenter, phase II study of PDR001 in patients with non-small cell lung cancer harboring KRAS/NRAS mutation or without actionable genetic abnormalities, detected using NGS platformKCT0002975Asan Medical Center70
招募中
1 期
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classesMultiple MyelomaCTIS2023-504273-21-00Pethema Fundacion50
进行中（未招募）
3 期
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistaminesChronic Spontaneous UrticariaBTK inhibitorJPRN-jRCT2061210066Hiroyuki Yamada70